PAREXEL partners with Korea Drug Development Fund

Thursday, July 19, 2012 02:29 PM

Boston-based CRO PAREXEL International announced it is the first CRO chosen by the Korea Drug Development Fund (KDDF) to help Korean companies develop and commercialize healthcare products for the global market.

"The KDDF is expected to be an important resource for emerging biopharmaceutical companies to advance their promising new technologies," said Ron Kraus, corporate vice president and worldwide head of PAREXEL Consulting and Medical Communications Services.

"The Korea Drug Development Fund is pleased to work with PAREXEL to establish various collaborative channels providing essential resources to Korean academic and research institutions and biopharmaceutical companies," said Dr. Dong Ho Lee, CEO of KDDF.

The KDDF is a consortium of three health-related Korean ministries: the Ministry of Knowledge Economy; the Ministry of Education, Science and Technology; and the Ministry of Health and Welfare. KDDF was established in September 2011 with $1 billion in assets to develop at least 10 new drugs by 2019 for the global market.

Its alliance with PAREXEL enhances its development network and will provide access to a range of drug development support services for its selected investments, tailored to the needs of Korean national companies and spanning the drug development continuum.

 

Share:          
CWWeekly

March 23

Industry welcomes FDA draft guidance outlining the use of electronic Informed Consent for trials

Apple launches ResearchKit platform to tap millions of iPhone users to enroll in observational studies using apps

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

March

Novo Nordisk, Takeda, Servier, Celgene among top sponsors
New gains seen from patient- and site-centric initiatives

Patient reported outcomes take center stage
FDA combining PROs, clinical outcomes in its approval decisions

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

February

Study grants market breaks $13 billion
Volume of clinical activity rising while growth in grant spending slows

Revisiting eClinical Technology Solutions Adoption
While use of established solutions grows, sponsors hesitate on newer tools

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs